Stefanie Flückiger-Mangual (left) and Julie Cherrington

Tol­re­mo rais­es $39M Se­ries A to ad­vance drug de­signed to dis­man­tle ear­ly can­cer de­fens­es

Tol­re­mo Ther­a­peu­tics has com­plet­ed a $39 mil­lion Se­ries A to fund a Phase I tri­al for its lead can­di­date in sol­id tu­mors. The com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.